Are the oil sector's low expectations a reason to buy? Mad Money's Cramer provides insight on a change in the space.» Read More
Are you ready skeedaddy???!!! It's time for the Lightning Round. Cramer makes the call on viewer favorites.
The pain may finally be coming to an end for these names, says “Mad Money” host Jim Cramer.
Jim Cramer speaks to the CEO of TherapeuticsMD on its venture to offer a new angle on hormone replacements that are not available currently.
Jim Cramer makes a call for investors to snap up these stocks in the oil patch. The positives cannot be ignored!
Jim Cramer is concerned with the amount of flooding in the market right now, and warns investors to watch out for these signs of a sinking ship.
GoDaddy soared more than 30 percent in its market debut Wednesday, leaving the pros split on whether they should get in on the action.
April has typically been the market's best-performing month, but Jack Bouroudjian thinks this year will be different.
The Fast Money traders share their final trades of the day.
Payment giants Intuit and Paychex go head to head as the the FM traders pick which stock will move onto the next round.
Jim Suva, Citigroup analyst, expects April to be an exciting month for tech giant Apple.
First quarter hedge fund results, with CNBC's Kate Kelly.
The Fast Money traders take a look at today's biggest market movers.
Louise Yamada, managing director at Louise Yamada Technical Research Advisors, goes to the charts on American Express.
Alex Gauna, JMP Securities, reacts to quarterly numbers by Micron and holds a buy rating on the stock.
Dissecting the day's trading action, with the Fast Money traders.
A stock brawl on GoDaddy with James Ramelli, Keeneonthemarkets.com, and Jason Rotman, Lido Isle Advisors.
On CNBC's "Fast Money," as part of their Madness challenge, the traders debate Paychex vs. Intuit.
Janus Capital's Contrarian Fund won the 2015 Lipper Award for best multi-cap core fund. Dan Kozlowski of Janus Capital Group, explains the contrarian strategy.
All eyes on the Fed as talk of rate hikes are underway. Bill Gross, Janus Global, gives his insight on what investors should expect on the topic of interest rates.
Sam Isaly, OrbiMed Advisors managing partner, says valuations are more than they used to be but adds, they're not crazy, they're sensible. He shares his view of the biotech sector.